Successful Alectinib Treatment for Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Gene: A Case Report
Gene alteration in anaplastic lymphoma kinase (ALK) is rare, and the efficacy of ALK inhibitors in the treatment of carcinoma of unknown primary (CUP) with <i>ALK</i> alteration remains unclear. The patient was a 56-year-old woman who presented with cervical lymph node swelling. Computed...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/3/180 |